SCHEMBL15713898

SCHEMBL15713898

NC(=S)n1nc(-c2ccc([N+](=O)[O-])cc2)cc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 1/20 0.44
CASP1 P29466 1/20 0.44
IKBKB O14920 1/20 0.43
RAD51 Q06609 1/20 0.42
MAPT P10636 6/20 0.41
THRB P10828 1/20 0.41
NPY5R Q15761 1/20 0.41
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EGFR P00533 3/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
MEN1 O00255 1/20 0.38
ESR1 P03372 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15713895 0.86 SCN4A (0.44) SCN4ACASP1IKBKBRAD51MAPT
SCHEMBL8471355 0.77 PHGDH (0.49) SCN4ACASP1RAD51MAPTTHRB
Hydrochloric Acid SCHEMBL9124640 0.74 SCN4A (0.43) SCN4ACASP1IKBKBRAD51MAPT
SCHEMBL15610305 0.71 MAPT (0.45) SCN4AIKBKBRAD51MAPTTHRB
SCHEMBL3393979 0.70 PDE4B (0.50) RAD51MAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL25433738 0.70 MAPT (0.50) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL29413798 0.69 RAD51 (0.44) SCN4ARAD51MAPTTHRBNPY5R
SCHEMBL12003368 0.69 BCHE (0.47) MAPTTHRBALDH1A1MEN1KMT2A
SCHEMBL3396698 0.69 GABRA1 (0.44) SCN4ACASP1RAD51ALDH1A1SMN1; SMN2
SCHEMBL14132597 0.68 ADORA2A (0.54) MAPTALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695127-B2 Compounds for treating HIV and methods for using the compounds University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-07-04 US disclosed
US-9695127-B2 Compounds for treating HIV and methods for using the compounds University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-07-04 US disclosed
US-20150291534-A1 COMPOUNDS FOR TREATING HIV AND METHODS FOR USING THE COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 US disclosed
US-20150291534-A1 COMPOUNDS FOR TREATING HIV AND METHODS FOR USING THE COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 US disclosed
WO-2014074628-A1 COMPOUNDS FOR TREATING HIV AND METHODS FOR USING THE COMPOUNDS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291534-A1 COMPOUNDS FOR TREATING HIV AND METHODS FOR USING THE COMPOUNDS PNMT, NEFM, DUT SCN4A 4343/4885CASP1 3007/4885IKBKB 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.